US2008187524A1PendingUtilityA1
Cellular Therapy to Heal Vascular Tissue
Est. expiryApr 25, 2023(expired)· nominal 20-yr term from priority
A61F 2002/077A61F 2002/065A61F 2/07A61P 7/00
54
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention encompasses methods and apparatus for minimizing the risks inherent in endovascular grafting for blood vessel therapy and repair. The invention involves delivering adult stem cells, embryonic stem cells, progenitor cells, fibroblasts, or smooth muscle cells to the diseased blood vessel.
Claims
exact text as granted — not AI-modified1 - 30 . (canceled)
31 . A method of treating an aneurysm in an individual at the aneurysmal site using self-derived cells, comprising:
harvesting adult stem cell-containing tissue from the individual wherein said tissue is selected from the group consisting of adipose tissue, bone marrow and peripheral blood; isolating adult stem cells from the tissue; and delivering the isolated adult stem cells directly to the wall of a blood vessel at said aneurysmal site by liquid delivery means wherein said blood vessel wall is repaired and said aneurysm is treated in said individual.
32 . The method of claim 31 , wherein the harvesting step is accomplished by liposuction, drawing blood, or harvesting bone marrow.
33 . The method of claim 31 , wherein the adult stem cells are isolated by growth in selective medium, by density centrifugation, fluorescence activated cell sorting or by magnetic activated cell sorting.
34 . The method of claim 31 , wherein the adult stem cells are isolated by assaying for adult stem cell-specific a actin, calponin, smooth muscle myosin heavy chain, β-tubulin or vimentin expression.
35 . The method of claim 31 , further comprising the step of modifying the adult stem cells after the isolating step.
36 . The method of claim 35 , wherein the modifying step is accomplished by genetic engineering.
37 . The method of claim 36 , wherein the adult stem cells are genetically engineered to produce at least one cellular factor selected from the group of collagen.Join the waitlist — get patent alerts
Track US2008187524A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.